|Positive WB detected in||HeLa cells|
|Positive IF detected in||HepG2 cells|
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
20032-1-AP targets SRC3/NCOA3 in WB, IHC, IF, ChIP, ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Full Name||nuclear receptor coactivator 3|
|Calculated molecular weight||155 kDa|
|Observed molecular weight||160 kDa|
|GenBank accession number||NM_006534|
|Gene ID (NCBI)||8202|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
NCOA3, also named as AIB1, SRC3 and TRAM1, belongs to the SRC/p160 nuclear receptor coactivator family. NCOA3 is a nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. NOCA3 plays a central role in creating a multisubunit coactivator complex, which probably acts via remodeling of chromatin. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ER), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). NCOA3 also involved in the coactivation of the NF-kappa-B pathway via its interaction with the NFKB1 subunit. The antibody can recognizes all the isoforms of NCOA3.
J Biol Chem
A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator
J Biol Chem
A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.
Pathological discrimination between luteinized thecoma associated with sclerosing peritonitis and thecoma